FDA Accepts NDA for SH-201 in Leukemia and Other Cancers
The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.
Stay updated with breaking news from Sharon Cunningham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.
Here are some start-ups from all over the world that are ones to watch in 2024, including some big players in AI, health and climate-tech.
The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.
Irish pharmaceutical company Shorla Oncology and consultancy firm Eversana have announced the U.S. launch of JYLAMVO, the first oral methotrexate solution.
Jylamvo, an FDA-approved oral solution formulation of methotrexate, is now available from Shorla Oncology and Eversana.